🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "huge turning point" in the effort against drug-resistant strains of the infection, according to health experts.

An International Health Concern

The sexually transmitted infection are increasing globally, with data suggesting in excess of 82 million new cases each year. Notably increased rates are seen in the African continent and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. In England, cases have reached a historical peak, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary development in the context of growing infection rates, the spread of superbugs and the highly restricted treatment choices presently on offer.”

Public health authorities are deeply concerned about the increase in treatment-resistant strains. The World Health Organization has classified it as a "critical concern". Ongoing monitoring found that the effectiveness of primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Receive Clearance

One new antibiotic, alternatively called a brand name, was authorized by the US Food and Drug Administration in recent days for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers anticipate that specific application of this new drug will help delay the emergence of superbugs.

Gepotidacin, created by the drugmaker GlaxoSmithKline, also received approval in concurrent days. This treatment, which is employed against urinary tract infections, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to develop it.

“This authorization marks a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Research Study Outcomes and Global Access

Based on findings released by a major medical journal, the new drug successfully treated the vast majority of uncomplicated infections. This puts it on an similar efficacy with the typical regimen, which combines a dual-drug approach. The research enrolled nearly 1,000 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the rights to register and commercialise the drug in many developing nations.

Doctors treating patients have voiced hope. Access to a single-dose, oral treatment like this is hailed as a "critical tool" for managing the epidemic. This is viewed as crucial to reduce the burden of the infection for patients and to stop the proliferation of untreatable gonorrhoea globally.